HY05350 / Huiyu Pharma - LARVOL DELTA

A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=262 | Not yet recruiting | Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd

New P1/2 trial • Solid Tumor

HY05350: A trispecific T-cell engager with immune checkpoint inhibitor targeting mesothelin for solid cancer (AACR 2025) - "We engineered a trispecific T cell engager HY05350 targeting CD3, MSLN and PD-L1 to treat solid cancers. Our in vitro and in vivo studies demonstrated that HY05350 was well-tolerated, induced strong T cell activation, cytotoxicity and potent antitumor efficacy, supporting for further clinical investigation."

Checkpoint inhibition • IO biomarker • Trispecific • Oncology • Solid Tumor • MSLN